MajesTEC-3
A bispecific plus daratumumab cut the risk of progression by more than 80% versus standard doublets, bringing bispecifics to second line.
PFS median not reached vs 18.1 months; 36-month PFS 83.4% vs 29.7% (HR ~0.17). Approved 5 March 2026 for ≥1 prior line; EU approval followed. Infection prophylaxis mandatory.
Setting
Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd
Phase
Phase 3
Sponsor
Janssen
Registry
Headline result
36-month PFS 83.4% vs 29.7%; HR ~0.17.
Reported
2025
Enrolled
587
In plain words
What these results mean for people, not percentages
Progression-free survival at 36 monthsprimarysurrogate endpoint
- 83.4 vs 29.7 out of 100 alive without the cancer growing at 36 months with Teclistamab + daratumumab compared with Dara-Pd / Dara-Vd; 53.7 more per 100.
- Roughly one extra person helped for every 2 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 83 percent lower chance of the event at any given time (hazard ratio 0.17).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.